300705 九典制药
已收盘 11-17 15:00:00
资讯
新帖
简况
九典制药:公司始终积极响应国家集采政策
证券之星 · 11-16 15:06
九典制药:公司始终积极响应国家集采政策
九典制药:涉及的药物临床研究均通过具备相应资质的机构进行伦理审查
证券之星 · 11-12
九典制药:涉及的药物临床研究均通过具备相应资质的机构进行伦理审查
九典制药:二期部分车间已投产,产能利用率较高
证券之星 · 11-12
九典制药:二期部分车间已投产,产能利用率较高
九典制药:椒七止痛凝胶贴膏获批上市后,公司正积极推进该产品在全国各省份的挂网工作
证券之星 · 11-06
九典制药:椒七止痛凝胶贴膏获批上市后,公司正积极推进该产品在全国各省份的挂网工作
九典制药:成为中国医药行业领跑者之一
证券之星 · 11-06
九典制药:成为中国医药行业领跑者之一
九典制药:主导品种执行集采致毛利率下行
证券之星 · 11-05
九典制药:主导品种执行集采致毛利率下行
九典制药:公司目前已上市针对烧心及胃食管反流等症状的药品
证券之星 · 11-04
九典制药:公司目前已上市针对烧心及胃食管反流等症状的药品
九典制药(300705)2026年三季报简析:净利润同比下降40.96%
证券之星 · 10-31
九典制药(300705)2026年三季报简析:净利润同比下降40.96%
股市必读:九典制药三季报 - 第三季度单季净利润同比下降30.19%
证券之星 · 10-30
股市必读:九典制药三季报 - 第三季度单季净利润同比下降30.19%
九典制药:公司未来的生产规划将紧密围绕整体发展战略,以市场需求为导向,科学安排生产计划,合理进行产能布局
证券之星 · 10-29
九典制药:公司未来的生产规划将紧密围绕整体发展战略,以市场需求为导向,科学安排生产计划,合理进行产能布局
九典制药:公司目前各项生产经营活动均正常、有序推进
证券之星 · 10-29
九典制药:公司目前各项生产经营活动均正常、有序推进
图解九典制药三季报:第三季度单季净利润同比下降30.19%
证券之星 · 10-29
图解九典制药三季报:第三季度单季净利润同比下降30.19%
九典制药(300705)9月30日股东户数3.35万户,较上期增加10.03%
证券之星 · 10-28
九典制药(300705)9月30日股东户数3.35万户,较上期增加10.03%
九典制药最新公告:子公司获盐酸溴己新口服溶液药品注册证书
证券之星 · 10-28
九典制药最新公告:子公司获盐酸溴己新口服溶液药品注册证书
九典制药:公司成功入选“2026年度卓越级智能工厂”名单
证券之星 · 10-28
九典制药:公司成功入选“2026年度卓越级智能工厂”名单
公司问答丨九典制药:关于股份回购、增持相关安排 现阶段公司暂未披露新的相关计划
格隆汇 · 10-23
公司问答丨九典制药:关于股份回购、增持相关安排 现阶段公司暂未披露新的相关计划
九典制药:公司暂无减肥药相关产品
证券之星 · 10-22
九典制药:公司暂无减肥药相关产品
集采冲击主业营利转跌,一笔募投连续转向未果最终补流,九典制药叙事逻辑迎考
市场资讯 · 10-10
集采冲击主业营利转跌,一笔募投连续转向未果最终补流,九典制药叙事逻辑迎考
九典制药(300705)披露获得铝碳酸镁混悬液药品注册证书公告,10月09日股价上涨2.93%
证券之星 · 10-09
九典制药(300705)披露获得铝碳酸镁混悬液药品注册证书公告,10月09日股价上涨2.93%
九典制药:公司现金流整体保持稳定
证券之星 · 10-09
九典制药:公司现金流整体保持稳定
加载更多
公司概况
公司名称:
湖南九典制药股份有限公司
所属行业:
医药制造业
上市日期:
2017-10-10
主营业务:
湖南九典制药股份有限公司的主营业务是化药制剂、原料药、药用辅料、中药、大健康产品的研发、生产、销售,以及药品零售、医药CXO服务、养生保健服务等。公司的主要产品是药品制剂、原料药、药用辅料。公司荣获“国家级绿色工厂”“长沙市示范性水载体”“湖南省绿色工厂”“环保示范企业”“环境保护先进单位”等荣誉。
发行价格:
10.37
{"stockData":{"symbol":"300705","market":"SZ","secType":"STK","nameCN":"九典制药","latestPrice":10.03,"timestamp":1794898995000,"preClose":10.11,"halted":0,"volume":3149427,"delay":0,"changeRate":-0.0079,"floatShares":370000000,"shares":500000000,"eps":0.6124,"marketStatus":"已收盘","change":-0.08,"latestTime":"11-17 15:00:00","open":10.05,"high":10.14,"low":9.98,"amount":31643900,"amplitude":0.0158,"askPrice":10.03,"askSize":2,"bidPrice":10.02,"bidSize":136,"shortable":0,"etf":0,"ttmEps":0.6124,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794965400000},"marketStatusCode":5,"adr":0,"adjPreClose":10.11,"symbolType":"stock","openAndCloseTimeList":[[1794879000000,1794886200000],[1794891600000,1794898800000]],"highLimit":11.12,"lowLimit":9.1,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":500294904,"isCdr":false,"pbRate":1.92,"roa":"--","peRate":16.378184,"roe":"9.11%","epsLYR":0.96,"committee":0.616162,"marketValue":5018000000,"turnoverRate":0.0085,"status":1,"floatMarketCap":3711000000},"requestUrl":"/m/hq/s/300705","defaultTab":"news","newsList":[{"id":"2683958226","title":"九典制药:公司始终积极响应国家集采政策","url":"https://stock-news.laohu8.com/highlight/detail?id=2683958226","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683958226?lang=zh_cn&edition=full","pubTime":"2026-11-16 15:06","pubTimestamp":1794812785,"startTime":"0","endTime":"0","summary":"请问在第13批集采中,公司对氟比洛芬的报价优先级是什么--是以中标为第一目标、接受较大降幅,还是设定一个价格底线、宁可丢标也不过度让利?据米内网数据显示,目前国内共有10家企业获批上市氟比洛芬凝胶贴膏,公司将持续发挥自身优势,积极应对市场竞争。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111600014654.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682410537","title":"九典制药:涉及的药物临床研究均通过具备相应资质的机构进行伦理审查","url":"https://stock-news.laohu8.com/highlight/detail?id=2682410537","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682410537?lang=zh_cn&edition=full","pubTime":"2026-11-12 11:36","pubTimestamp":1794454580,"startTime":"0","endTime":"0","summary":"证券之星消息,九典制药11月11日在投资者关系平台上答复投资者关心的问题。关注到公司主营激素及调节内分泌功能类制剂。临床研究的伦理审查现由内部、合作医院还是外部机构承担?","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111200014902.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300705"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682374485","title":"九典制药:二期部分车间已投产,产能利用率较高","url":"https://stock-news.laohu8.com/highlight/detail?id=2682374485","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682374485?lang=zh_cn&edition=full","pubTime":"2026-11-12 11:36","pubTimestamp":1794454578,"startTime":"0","endTime":"0","summary":"证券之星消息,九典制药11月11日在投资者关系平台上答复投资者关心的问题。请问:1. 截至目前,二期生产线是否已经正式开始投料试生产?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111200014898.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300705"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681882612","title":"九典制药:椒七止痛凝胶贴膏获批上市后,公司正积极推进该产品在全国各省份的挂网工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2681882612","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681882612?lang=zh_cn&edition=full","pubTime":"2026-11-06 09:03","pubTimestamp":1793926996,"startTime":"0","endTime":"0","summary":"2. 今年的国家医保谈判中,椒七是否已经按计划提交了相关材料并进入谈判流程?","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110600009267.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681653882","title":"九典制药:成为中国医药行业领跑者之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2681653882","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681653882?lang=zh_cn&edition=full","pubTime":"2026-11-06 09:03","pubTimestamp":1793926995,"startTime":"0","endTime":"0","summary":"证券之星消息,九典制药(300705)11月05日在投资者关系平台上答复投资者关心的问题。投资者提问:请问贵公司对公司未来发展有没有奋斗的目标?比如成为五百亿市值龙头,千亿市值大公司之类的。九典制药回复:尊敬的投资者您好,公司的发展愿景是成为中国医药行业领跑者之一。公司始终专注于主业经营,致力于持续提升研发创新能力、丰富产品管线、夯实核心竞争力,努力推动公司高质量、可持续发展。感谢您对公司的关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:陈思雨","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110600009265.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","600056","BK0185","BK1610","BK0188","BK0239","300705","BK0175","BK0250","03069","BK0010","BK0082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681090814","title":"九典制药:主导品种执行集采致毛利率下行","url":"https://stock-news.laohu8.com/highlight/detail?id=2681090814","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681090814?lang=zh_cn&edition=full","pubTime":"2026-11-05 08:54","pubTimestamp":1793840047,"startTime":"0","endTime":"0","summary":"在建工程转固导致的利息费用化,是否已经在Q3一次性计提完毕?九典制药回复:尊敬的投资者您好,公司2026年前三季度净利润同比下降,主要系主导品种洛索洛芬钠凝胶贴膏执行国家集中带量采购,产品价格下调使得毛利率显著下行;同时,品牌建设投入加大、相关无形资产摊销增加及项目贷款对应在建工程转固后利息支出费用化等因素,亦对本期利润产生影响。公司将根据经营实际统筹安排品牌投入及各项费用支出,努力提升费用使用效率。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110500010294.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680008822","title":"九典制药:公司目前已上市针对烧心及胃食管反流等症状的药品","url":"https://stock-news.laohu8.com/highlight/detail?id=2680008822","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680008822?lang=zh_cn&edition=full","pubTime":"2026-11-04 11:36","pubTimestamp":1793763383,"startTime":"0","endTime":"0","summary":"最近全网都在聊“贵是贵了点,但吃了不烧心”,想咨询下公司有没有对应烧心、胃食管反流的已上市药品?上述品种获批上市后,将进一步扩充公司在消化系统领域的产品矩阵。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110400017009.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679226834","title":"九典制药(300705)2026年三季报简析:净利润同比下降40.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679226834","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679226834?lang=zh_cn&edition=full","pubTime":"2026-10-31 07:53","pubTimestamp":1793404436,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期九典制药发布2026年三季报。根据财报显示,九典制药净利润同比下降40.96%。截至本报告期末,公司营业总收入20.49亿元,同比下降9.67%,归母净利润2.4亿元,同比下降40.96%。按单季度数据看,第三季度营业总收入7.62亿元,同比上升0.77%,第三季度归母净利润8024.02万元,同比下降30.19%。本次财报公布的各项数据指标表现一般。去年的净利率为15.11%,算上全部成本后,公司产品或服务的附加值高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103100017424.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679225836","title":"股市必读:九典制药三季报 - 第三季度单季净利润同比下降30.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679225836","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679225836?lang=zh_cn&edition=full","pubTime":"2026-10-30 06:56","pubTimestamp":1793314619,"startTime":"0","endTime":"0","summary":"业绩披露要点:九典制药2026年三季报显示,前三季度归母净利润2.4亿元,同比下降40.96%。董秘最新回复投资者: 请问贵公司股票一直下行,有什么市值管理的措施吗?","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000012766.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679400167","title":"九典制药:公司未来的生产规划将紧密围绕整体发展战略,以市场需求为导向,科学安排生产计划,合理进行产能布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2679400167","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679400167?lang=zh_cn&edition=full","pubTime":"2026-10-29 20:48","pubTimestamp":1793278116,"startTime":"0","endTime":"0","summary":"证券之星消息,九典制药(300705)10月29日在投资者关系平台上答复投资者关心的问题。投资者提问:请问公司未来的生产规划是什么样的九典制药回复:尊敬的投资者您好,公司未来的生产规划将紧密围绕整体发展战略,以市场需求为导向,科学安排生产计划,合理进行产能布局。感谢您对公司的关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102900058575.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300705"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679424618","title":"九典制药:公司目前各项生产经营活动均正常、有序推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2679424618","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679424618?lang=zh_cn&edition=full","pubTime":"2026-10-29 15:03","pubTimestamp":1793257401,"startTime":"0","endTime":"0","summary":"证券之星消息,九典制药(300705)10月29日在投资者关系平台上答复投资者关心的问题。投资者提问:请问贵公司三季度业绩这么拉胯,四季度有改善计划吗?谢谢九典制药回复:尊敬的投资者您好,公司目前各项生产经营活动均正常、有序推进。四季度,公司将继续围绕年度经营目标,扎实推进各项业务开展,积极应对市场环境及政策变化,努力做好市场拓展工作。感谢您对公司的关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102900032513.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679604490","title":"图解九典制药三季报:第三季度单季净利润同比下降30.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679604490","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679604490?lang=zh_cn&edition=full","pubTime":"2026-10-29 01:13","pubTimestamp":1793207582,"startTime":"0","endTime":"0","summary":"证券之星消息,九典制药2026年三季报显示,前三季度公司主营收入20.49亿元,同比下降9.67%;归母净利润2.4亿元,同比下降40.96%;扣非净利润2.3亿元,同比下降41.22%;其中2026年第三季度,公司单季度主营收入7.62亿元,同比上升0.77%;单季度归母净利润8024.02万元,同比下降30.19%;单季度扣非净利润8079.08万元,同比下降25.36%;负债率35.76%,投资收益-171.8万元,财务费用2323.44万元,毛利率61.85%。财报数据概要请见下图:本文数据来源于九典制药2026年三季报,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102900003162.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678661954","title":"九典制药(300705)9月30日股东户数3.35万户,较上期增加10.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678661954","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678661954?lang=zh_cn&edition=full","pubTime":"2026-10-28 18:50","pubTimestamp":1793184655,"startTime":"0","endTime":"0","summary":"证券之星消息,近日九典制药披露,截至2026年9月30日公司股东户数为3.35万户,较6月30日增加3051.0户,增幅为10.03%。在化学制药行业个股中,九典制药股东户数低于行业平均水平,截至9月30日,化学制药行业平均股东户数为3.9万户。从股价来看,2026年6月30日至2026年9月30日,九典制药区间涨幅为13.19%,在此期间股东户数增加3051.0户,增幅为10.03%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102800041344.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300705"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678454485","title":"九典制药最新公告:子公司获盐酸溴己新口服溶液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2678454485","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678454485?lang=zh_cn&edition=full","pubTime":"2026-10-28 17:00","pubTimestamp":1793178009,"startTime":"0","endTime":"0","summary":"九典制药(300705.SZ)公告称,公司全资子公司湖南普道医药技术有限公司近日收到国家药品监督管理局下发的《药品注册证书》,药品名称为盐酸溴己新口服溶液,规格为40ml:80mg,注册分类为化学药品3类。该药品适用于成人、青少年及6岁及以上儿童的粘液分泌或粘液清除障碍相关呼吸系统疾病的对症治疗。截至公告日,国内共有21家企业取得该药品注册证书。公司表示,此次取得注册证书丰富了公司产品管线,对优化产品结构有积极意义。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102800037419.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678546214","title":"九典制药:公司成功入选“2026年度卓越级智能工厂”名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2678546214","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678546214?lang=zh_cn&edition=full","pubTime":"2026-10-28 16:57","pubTimestamp":1793177830,"startTime":"0","endTime":"0","summary":"证券之星消息,九典制药(300705)10月28日在投资者关系平台上答复投资者关心的问题。投资者提问:请问贵公司有考虑引进先进的生产技术来降低成本吗?谢谢九典制药回复:尊敬的投资者您好,公司始终高度重视生产端的降本增效工作,并持续推进生产制造的数字化、智能化升级。近日,公司成功入选工信部公布的“2026年度卓越级智能工厂”名单,这标志着公司在智能制造和精益生产方面取得了积极成效。未来,公司将继续通过引进先进生产技术、优化生产工艺及深化数字化应用等方式,不断提升生产效率和成本控制能力。感谢您对公司的关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102800037009.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300705"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677351942","title":"公司问答丨九典制药:关于股份回购、增持相关安排 现阶段公司暂未披露新的相关计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2677351942","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677351942?lang=zh_cn&edition=full","pubTime":"2026-10-23 16:58","pubTimestamp":1792745938,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["300705","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677867999","title":"九典制药:公司暂无减肥药相关产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2677867999","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677867999?lang=zh_cn&edition=full","pubTime":"2026-10-22 08:30","pubTimestamp":1792629024,"startTime":"0","endTime":"0","summary":"证券之星消息,九典制药(300705)10月21日在投资者关系平台上答复投资者关心的问题。投资者提问:请问贵公司有减肥药一类产品吗?谢谢九典制药回复:尊敬的投资者您好,公司暂无减肥药相关产品。感谢您对公司的关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:陈思雨","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102200006989.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300705"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674994528","title":"集采冲击主业营利转跌,一笔募投连续转向未果最终补流,九典制药叙事逻辑迎考","url":"https://stock-news.laohu8.com/highlight/detail?id=2674994528","media":"市场资讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674994528?lang=zh_cn&edition=full","pubTime":"2026-10-10 15:45","pubTimestamp":1791618300,"startTime":"0","endTime":"0","summary":"拉长时间线看,九典制药的营收增速已连续多年放缓。从收入结构来看,药品制剂是九典制药的基本盘。九典制药表示,洛索洛芬钠凝胶贴膏在第十一批全国集采降价74.25%,2025年其营业收入约占公司整体营收的45%,公司整体毛利水平预期降低,公司的营业收入增速放缓。尽管该板块出现增长,但难以补齐药品制剂下滑的缺口。2025年8月,九典制药将原募投项目变更为“抗菌多肽新药研发项目”,并将剩余未投入金额约9808.93万元全部投入新项目。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2026-10-10/doc-iniutqmk0645186.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["300705","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674830753","title":"九典制药(300705)披露获得铝碳酸镁混悬液药品注册证书公告,10月09日股价上涨2.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2674830753","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674830753?lang=zh_cn&edition=full","pubTime":"2026-10-09 17:39","pubTimestamp":1791538752,"startTime":"0","endTime":"0","summary":"截至2026年10月9日收盘,九典制药报收于11.23元,较前一交易日上涨2.93%,最新总市值为56.18亿元。该股当日开盘10.89元,最高11.27元,最低10.8元,成交额达1.71亿元,换手率为4.16%。该药品适用于慢性胃炎及与胃酸有关的胃部不适症状,具有抗酸、胃黏膜保护和胆酸吸附作用。目前国内已有10家企业取得该品种注册证书。药品的生产和销售受行业政策、市场环境等因素影响,存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900027815.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674831761","title":"九典制药:公司现金流整体保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=2674831761","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674831761?lang=zh_cn&edition=full","pubTime":"2026-10-09 15:45","pubTimestamp":1791531909,"startTime":"0","endTime":"0","summary":"证券之星消息,九典制药(300705)10月08日在投资者关系平台上答复投资者关心的问题。投资者提问:请问贵公司当前现金流如何?谢谢九典制药回复:尊敬的投资者您好,公司现金流整体保持稳定,账面资金可充分保障日常生产经营及研发投入所需。现金流详细数据请查阅公司已披露的定期报告。感谢您对公司的关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:沈彬","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900020395.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","159399","300705"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1794902776642,"stockEarnings":[{"period":"1week","weight":-0.0362},{"period":"1month","weight":-0.0639},{"period":"3month","weight":-0.1483},{"period":"6month","weight":-0.1106},{"period":"1year","weight":-0.3892},{"period":"ytd","weight":-0.3024}],"compareEarnings":[{"period":"1week","weight":-0.0159},{"period":"1month","weight":-0.0306},{"period":"3month","weight":-0.0972},{"period":"6month","weight":-0.1345},{"period":"1year","weight":-0.0972},{"period":"ytd","weight":-0.0923}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"湖南九典制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"33460人(较上一季度增加10.03%)","perCapita":"11056股","listingDate":"2017-10-10","address":"湖南省长沙市浏阳市经济技术开发区健康大道1号","registeredCapital":"50029万元","survey":" 湖南九典制药股份有限公司的主营业务是化药制剂、原料药、药用辅料、中药、大健康产品的研发、生产、销售,以及药品零售、医药CXO服务、养生保健服务等。公司的主要产品是药品制剂、原料药、药用辅料。公司荣获“国家级绿色工厂”“长沙市示范性水载体”“湖南省绿色工厂”“环保示范企业”“环境保护先进单位”等荣誉。","listedPrice":10.37},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.54.0","shortVersion":"4.54.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"九典制药(300705)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供九典制药(300705)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"九典制药,300705,九典制药股票,九典制药股票老虎,九典制药股票老虎国际,九典制药行情,九典制药股票行情,九典制药股价,九典制药股市,九典制药股票价格,九典制药股票交易,九典制药股票购买,九典制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"九典制药(300705)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供九典制药(300705)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}